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1. Introduction
The cell surface displays a complex array of oligosaccharides, glycoproteins, and
glycolipids. This diverse mixture of glycans contains a wealth of information, modulating a
wide range of processes such as cell migration, proliferation, transcriptional regulation, and
differentiation.1–5 Glycosylation is one of the most ubiquitous forms of post-translational
modification, with more than 50% of the human proteome estimated to be glycosylated.6
Glycosylation adds another dimension to the complexity of cellular signaling and expands
the ability of a cell to modulate protein function. The structural complexity of glycan
modifications ranges from the addition of a single monosaccharide unit to polysaccharides
containing hundreds of sugars in branched or linear arrays.7 This chemical diversity enables
glycans to impart a vast array of functions, from structural stability and proteolytic
protection to protein recognition and modulation of cell signaling networks.8,9–12
Emerging evidence suggests a pivotal role for glycans in regulating nervous system
development and function. For instance, glycosylation influences various neuronal
processes, such as neurite outgrowth and morphology, and may contribute to the molecular
events that underlie learning and memory.7,13,14 Glycosylation is an efficient modulator of
cell signaling and has been implicated in memory consolidation pathways.15–18 Genetic
ablation of glycosylation enzymes often leads to developmental defects and can influence
various organismal behaviors such as stress and cognition.19–24 Thus, the complexity of
glycan functions help to orchestrate proper neuronal development during embryogenesis, as
well as influence behaviors in the adult organism.
The importance of glycosylation is further highlighted by defects in glycan structures that
often lead to human disease, as exhibited by congenital disorders of glycosylation
(CDG).25–29 These are usually inherited disorders resulting from defects in glycan
biosynthesis, which are accompanied by severe developmental abnormalities, mental
retardation, and difficulties with motor coordination. Such disorders highlight the
importance of glycan biosynthesis in human health and development. Because therapeutic
treatments are currently limited, investigations into the structure–activity relationships of
glycans, as well as disease-associated alterations to glycan structure, are crucial for
developing strategies to combat these diseases.
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Understanding the structure–function relationships of glycans has been hampered by a lack
of tools and methods to facilitate their analysis. In contrast to nucleic acids and proteins,
oligosaccharides often have branched structures, and their biosynthesis is not template-
encoded. As such, the composition and sequence of oligosaccharides cannot be easily
predicted, and genetic manipulations are considerably less straightforward. Analytical
techniques for investigating oligosaccharide composition, sequence, and tertiary structure
are still undergoing development and are far from routine, unlike methods for DNA and
protein analysis. Lastly, glycan structures are not under direct genetic control and, thus, are
often heterogeneous. This heterogeneity complicates structure–function analyses by
traditional biochemical approaches that rely on the isolation and purification of glycans from
natural sources.
The problems associated with oligosaccharide analysis have hindered efforts to understand
the biology of oligosaccharides yet have given chemists a unique opportunity to develop
new methods to overcome these challenges. The development of chemical tools for the
analysis of glycan structure and function is essential to advance our understanding of the
roles of glycoconjugates in regulating diverse biological processes. In this review, we will
highlight the emerging area of glyconeurobiology with an emphasis on current chemical
approaches for elucidating the biological functions of glycans in the nervous system.
2. Sialic Acids
2.1. Structure
Sialic acids participate in a multitude of biologically interesting phenomena, including cell–
cell recognition, adhesion, and intracellular signaling events.30–32 Originally known as
neuraminic acid (Neu) and its derivatives, sialic acids are a family of α-keto acids
containing a nine-carbon backbone.32 The most well-known members of the sialic acid
family include N-acetylneuraminic acid (Neu5Ac), N-glycolylneuraminic acid (Neu5Gc),
and deaminoneuraminic acid (KDN) (Figure 1). In addition to these basic forms, more than
50 distinct sialic acid structures have been identified in nature, arising from acetylation,
methylation, lactylation, sulfation, and phosphorylation of the C-4, C-5, C-7, C-8, or C-9
hydroxyl groups.
Sialic acids exist predominantly as terminal monosaccharides linked to galactose residues in
glycan chains through α(2–3)- or α(2–6)-linkages. They can also form a ho-mopolymer of
α(2–8)-linked sialic acid in mammals, termed polysialic acid (PSA).33,34 As discussed
below, each glycoform dictates a unique function to the glycoproteins and glycolipids
expressing these sugars. Sialic acids have historically received much attention due to their
participation in cell–cell recognition events and the pathogenesis of diseases such as
cancer,35–37 inflammatory disease,38–40 and viral infection.41–44 The development of sialic
acid analogues as inhibitors or probes for biomedical research has led to significant
advances in our understanding of this important family of carbohydrates. Here, we will
discuss some of the roles of sialic acids in neurobiology and chemical approaches that have
provided insight into their functions.
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2.2.1. α(2–3)-Sialic Acid and Myelin-Associated Glycoprotein—Sialic acid is often
expressed as α(2–3)-linked sialic acid in the nervous system, a carbohydrate motif
recognized by the Siglec (sialic acid-binding immunoglobulin-like lectin) family of proteins.
Human Siglecs include at least 13 members, each containing a common V-set
immunoglobulin domain that interacts with sialic acid.45 One interaction that has been
extensively studied is the binding of myelin-associated glycoprotein (MAG; also known as
Siglec-4) with α(2–3)-sialic acid. MAG is a 100-kDa integral membrane glycoprotein that is
expressed myelinating glia cells.46,47 It is involved in regulating the formation and
maintenance of myelin48 and has been suggested to inhibit nerve regeneration in the adult
central nervous system (CNS).49–51 Mice deficient in MAG display delayed myelination,52
defects in the organization of periaxonal space,53 and subtle morphological abnormalities of
myelin sheaths.52 The interactions of MAG with sialic acid-containing glycosphingolipids,
known as gangliosides, have been extensively studied and have contributed to our
understanding the role of MAG in myelin formation and neural regeneration.
MAG preferentially binds the glycan structure Neu5Acα-(2–3)Galβ(1–3)GalNAc,54 which
is expressed on cell-surface gangliosides and O-glycans of glycoproteins.47 Gangliosides
represent the major source of sialic acid expression in the brain. MAG binds with high
affinity and specificity to the major brain gangliosides GD1a and GT1b, as well as the
polysialoganglioside GQ1bα, a minor ganglioside expressed on cholinergic neurons (Figure
2). Digestion of gangliosides purified from bovine brain with neuraminidase, an enzyme that
cleaves sialic acid residues, eliminated the binding of MAG to these gangliosides,
demonstrating the importance of the sialic acid moiety in mediating MAG–ganglioside
interactions.55–57
Studies suggest that the association of MAG with sialic acid-containing gangliosides plays
an important functional role in neuronal growth. The ability of MAG to inhibit neurite
outgrowth in vitro is blocked by treatment of cerebellar granule neurons with neuraminidase
or with the glucosyl-ceramide synthase inhibitor P4, which prevents synthesis of all
glycosphingolipids.55 Moreover, mice lacking the glycosyltransferase gene GalNAcT (UDP-
N-acetylgalactosamine: GM3/GD3 N-acetylgalactosaminyltransferase) do not express
complex gangliosides such as GD1a and GT1b and, as a consequence, exhibit axon
degeneration and gross dysmyeli-nation.58,59 These mice also display progressive behavioral
abnormalities consistent with neurodegenerative disease, such as defects in balance,
reflexes, and motor coordination.59 Thus, detailed knowledge of MAG and its interactions
with sialylated glycans may enhance our understanding of myelinating disorders such as
multiple sclerosis and provide opportunities to enhance axon regeneration after CNS injury
or disease.
2.2.2. Polysialic Acid—In the brain, PSA is expressed primarily on the protein neural cell
adhesion molecule (NCAM).60–62 NCAM plays critical roles in both nervous system
development and memory formation, regulating processes such as cell adhesion, axon
targeting and fasciculation, neuronal migration, synaptic plasticity, and
synaptogenesis.60,61,63–70 PSA–NCAM is highly expressed in the embryonic brain71–73 and
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is found in the adult brain in areas that retain a high degree of plasticity and neurogenesis,
such as the hippocampus, olfactory bulb, and hypothalamus.74–77
Although the molecular mechanisms underlying PSA function are not well understood, PSA
is thought to modulate cell–cell adhesion by attenuating homophilic NCAM–NCAM
interactions. The large steric bulk and hydration shell of the carbohydrate chain increase the
intercellular space by 10–15 μm, reducing trans NCAM–NCAM interactions across
apposing cells.78 In addition, PSA modulates the interactions of NCAM with other proteins,
such as heparan sulfate proteoglycans involved in the formation and remodeling of
hippocampal synapses.79 The PSA chains on NCAM have also been proposed to play a role
in some neuropsychiatric disorders. For example, expression of PSA–NCAM is significantly
reduced in the hippocampus of schizophrenic patients and may contribute to the complex
symptoms associated with the disease.80–82 Moreover, PSA has been implicated in the
etiology of Alzheimer’s disease, as PSA–NCAM-positive granule cells are increased in the
hippocampus of Alzheimer’s patients and are associated with disorganization of PSA-
positive fibers.83 Finally, PSA may also regulate neuronal function through NCAM-
independent mechanisms. For example, PSA has been suggested to act as a competitive
antagonist of the NMDA receptor, an ionotropic glutamate channel involved in synaptic
transmission,84 thereby preventing glutamate-induced excitotoxicity.85
Despite intriguing roles for sialic acid-containing glycans, the molecular mechanisms
underlying their diverse functions in the brain remain largely unknown. As described below,
chemical approaches to access and manipulate sialic acid structures have expanded our
understanding of the neuro-biological roles of sialic acid and promise to continue to advance
the field.
2.3. Chemical Neurobiology of Sialic Acid
2.3.1. Synthetic Sialic Acid Derivatives: Probing the Specificity of MAG
Interactions—Synthetic sialic acid analogues have been used to elucidate the molecular
determinants important for MAG-ganglioside interactions. The C-9 hydroxyl group
represents a key recognition element: substitution of this group with hydrogen, halogen, or
thiol groups attenuated the association of MAG with Neu5Ac (Figure 3, compounds 1–5).
Interestingly, an amino group at C-9 enhanced binding to MAG by 3-fold, suggesting the
importance of a hydrogen donor at this position (compound 6).86 The C-5 N-acetyl group of
Neu5Ac was also found to be critical for MAG binding, although it is not always required
for interaction with other Siglecs. Replacement of this group with an N-propanoyl, N-
aminoacetyl, or N-thioacetyl moiety enhanced binding of sialic acid to MAG by up to 4-fold
(compounds 7–9). The corresponding halogenated derivatives were all found to increase the
binding to MAG (compounds 10–13), with the monofluorinated derivative achieving a 17-
fold increase in potency. In contrast, amino substitution at the C-5 position significantly
attenuated binding to MAG.86 Together, these studies highlight key interactions between
MAG and the C-9 hydroxyl and C-5 N-acetyl groups of sialic acid.
In addition to probing monosaccharide variants, numerous oligosaccharide derivatives have
been synthesized and tested for binding to MAG. These structures mimic naturally occurring
ganglioside structures such as GD1a (Figure 2). Consistent with previous studies,
Murrey and Hsieh-Wilson Page 4













substitution of the C-9 hydroxyl of Neu5Ac with a methyl group within the trisaccharide
Neu5Acα(2–3)Galβ(1–4)Glc attenuated binding to MAG by 5-fold, again highlighting the
importance of the glycerol side chain.87 These results are consistent with an X-ray crystal
structure of the Siglec sialoadhesin complexed with sialyllactose, in which the C-9 hydroxyl
group of NeuAc forms a hydrogen bond with the amide backbone of Leu-107.88 Although
these proteins are distinct, it is conceivable that their mode of binding to sialic acid would be
conserved across Siglec family members. In contrast to C-9, the C-7 and C-4 hydroxyls do
not appear to contribute substantially to the binding energy of MAG–sialic acid
interactions.87 The C-7 deoxy derivative of Neu5Acα(2–3)-Gal(β(1–4)Glcβ-2-azidoethyl
exhibited only slightly enhanced binding to MAG (1.5-fold), whereas the C-4 deoxy
derivative showed slightly decreased binding (2-fold). However, both the C-7 and C-4
hydroxyls appeared to be critical for binding when placed in the context of a polyvalent
array.57 Thus, valency and cell-surface presentation may reflect another facet of the complex
regulation and specificity of Siglec–ganglioside interactions.
Synthetic oligosaccharide derivatives have also provided insight into the importance of
specific glycosidic linkages and other residues within the structure. MAG was found to bind
5-fold better to α(2–3)-linked Neu5Ac than to α(2–6)-linked Neu5Ac in synthetic
trisaccharides.87 Interestingly, replacement of Neu5Ac in a pentasaccharide structure with
the naturally occurring sialic acid KDN led to a 6.5-fold increase in MAG binding,87
suggesting that other sialic acid forms may bind MAG in vivo. In addition to contacts with
terminal sialic acid residues, internal sugars were also found to be important for MAG
interactions. For instance, substitution of the C-4 hydroxyl group of galactose in
Neu5Acα(2–3)-Galβ(1–4)Glc with a hydrogen atom enhanced binding to MAG by 2.3-fold.
Changing this residue to GalNAc, adding an O-methyl substituent at C-6, or exchanging the
ring oxygen to an N-methyl or N-butyl functionality decreased the potency of the
trisaccharide.87 Modifications of the third glucose residue to N-acetylglucosamine (GlcNAc)
also decreased the binding properties of the molecules. Various substitutions of the N-acetyl
group, such as N-phthaloyl or N-octanoyl substituents, increased the potency of the
compounds, which reflects the potential for a hydrophobic interaction with MAG at this
site.87 Lastly, pentasaccharides of the structure Neu5Acα(2–3)Galβ(1–4)AllNAcβ(1–3)-
Galβ(1–4)Glcβ–2-(trimethylsilyl)ethyl (AllNAc = N-acetyl-allosamine) were found to
increase binding above the trisaccharide Neu5Acα(2–3)Galβ(1–4)Glc by ~6-fold,
suggesting even more extensive contacts between MAG and the interior residues of large
glycan structures.87
Together, studies using synthetic analogues have illustrated how subtle perturbations to the
sialic acid core structure can have significant effects on protein binding. As described below,
such studies may facilitate the design of novel synthetic inhibitors of MAG function with
therapeutic potential.
2.3.2. Development of MAG Antagonists with Therapeutic Potential—The
importance of MAG–ganglioside interactions for nerve regeneration and myelination has
inspired the design and synthesis of small molecules capable of disrupting those interactions.
Such molecules have the potential to enhance nerve regeneration by blocking the inhibitory
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effects of MAG on neurite outgrowth. Below, we provide some examples of small molecule
antagonists that exhibit activity in cellular regeneration models.
Paulson and co-workers examined the interactions of monovalent sialic acid derivatives with
MAG and other Siglec family members.89 Over 25 derivatives representing most of the
major sialic acid structures found on glycoproteins and glycolipids were tested. The most
potent inhibitor of MAG–ganglioside interactions was the disialyl structure Neu5Acα(2–
3)Galβ (1–3)[Neu5Acα(2–6)]GalNAcα-O-ThrOCH3 (Figure 4A), which exhibited an IC50
value of 0.3 μM. This compound showed greater than 12000-fold enhanced potency relative
to Neu5Ac for inhibiting MAG–sialic acid interactions.89
The disialyl structure above and other potent inhibitors such as Neu5Acα(2–3)Galβ (1–
3)GalNAc were subsequently tested for their ability to attenuate MAG-mediated inhibition
of neurite outgrowth.90 When rat cerebellar granule neurons (CGN) are cultured on a
substratum of myelin-extracted proteins, they project fasciculated axons and cluster
together, leaving the majority of the substrata bare. This form of neuronal growth inhibition
is mediated primarily by MAG. The sialosides relieved the MAG-dependent inhibition of
CGN neurons, enhancing nerve regeneration in a dose-dependent manner and proportional
to their relative binding affinities for MAG.90 The most potent compound, the disialyl
structure, completely reversed the inhibition induced by MAG. Thus, synthetic glycans can
effectively enhance neurite outgrowth in vitro and, when used in combination with other
treatments, may provide a means to improve functional recovery after neuronal injury. The
ability to compare various Siglec family members against a large number of sialoside
structures has also revealed the specificity of Siglecs for different carbohydrate epitopes and
may help to fine-tune the development of selective MAG antagonists.
Many oligosaccharide-based inhibitors are synthetically challenging to produce and can
suffer from poor pharmacokinetics. As an alternative to this approach, Ernst and coworkers
generated structurally simplified mimics of the ganglioside GQ1bα. In particular, the Gal
and GalNAc residues in the trisaccharide Neu5Acα(2–3)Galβ (1–3)GalNAc were replaced
with an α-linked benzyl ether moiety, and aromatic residues were positioned on the glycerol
side chain (Figure 4B). Despite its smaller size, this compound displayed a remarkable
1000-fold enhanced binding affinity relative to the trisaccharide Neu5Acα(2–3)Galβ (1–
3)Gal-NAcβ-2-(trimethylsilyl)ethyl. Although the compound was not tested in cellular
regeneration assays, it was anticipated to have improved pharmacokinetic properties due to
its lower molecular weight and favorable Clog P value.91–93 Similar approaches may yield
additional therapeutic leads with the desired inhibitory potency and pharmacokinetics for the
treatment of demyelinating disorders.
2.3.3. Synthetic Mimics of α(2–8)-Linked PSA for Nerve Regeneration—PSA
expression is generally considered a permissive determinant in areas of neuronal growth and
plasticity, making it a potential therapeutic target for neuronal regeneration. In fact,
expression of PSA has been shown to promote functional recovery and provide a favorable
environment for axonal regeneration in animal models of spinal cord injury.94,95 In these
studies, PSA–NCAM was ectopically expressed in spinal cord astrocytes in vivo,94 or PSA-
expressing Schwann cell grafts were employed.95 Although the use of PSA oligo- and
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polysaccharides may be viable alternatives, PSA isolated from natural sources is often
heterogeneous in length and can be contaminated with other cell-surface glycans. In
addition, PSA adopts a helical conformation96 and forms filament bundles,97 thus exhibiting
different structural elements that may have distinct functions.
To circumvent these challenges, Rougon, Schachner, and co-workers screened a large
peptide library to identify potential PSA mimetics.98 Two cyclic peptides were identified
that recapitulated the properties of endogenous PSA. Both compounds stimulated the
outgrowth and defasciculation of mouse dorsal root ganglion (DRG) neurons and promoted
neuronal migration in vitro and in vivo. In addition, one peptide enhanced the migration of
transplanted neuronal progenitor cells in the murine olfactory bulb in vivo via a pathway
known to be regulated by PSA.98 Thus, synthetic mimics may provide novel alternatives to
PSA for neuronal regeneration.
2.3.4. Metabolic Labeling To Remodel Cell-Surface Sialic Acid Interactions—
The metabolic labeling of glycan chains with unnatural sugars has played a key role in
expanding the knowledge of sialic acid function in the nervous system. Early studies by
Reuttar and colleagues demonstrated that unnatural chemical functionalities could be
incorporated into cell-surface sialylglycoconjugates by the addition of N-
acetylmannosamine analogues (ManNAc; Figure 5A) to cells.99–103 ManNAc is the first
committed intermediate in the sialic acid biosynthetic pathway, and the enzymes in this
metabolic pathway are promiscuous for some unnatural substrates.104–106 As described
below, the ability to alter the structures of sialylglycoconjugates has provided key insights
into the roles of sialic acid in neuronal migration and proliferation.
2.3.4.1. Metabolic Labeling of Neurons with Elongated N-Acyl Derivatives of Sialic
Acid: Elongated N-acyl derivatives of ManNAc have been incorporated into
sialylglycoconjugates of PC12 cells, oligodendrocyte progenitor cells, microglia, astrocytes,
and neurons from cerebellar microex-plant cultures.101,107 In these studies, cells were
treated with N-propanoylmannosamine (ManNProp), wherein the N-acetyl substituent of
Neu5Ac is replaced with a longer N-propanoyl group (Figure 5A). ManNProp was found to
stimulate the proliferation of microglia relative to cells treated with the natural sialic acid
precursor, ManNAc.107 ManNProp also induced the migration of oligodendrocyte
progenitor cells, the precursors to oligodendrocyte cells, which play key roles in myelin
formation and become functionally impaired in neurological diseases such as multiple
sclerosis.108–112 Interestingly, treatment with ManNProp prolonged expression of a
sialylated ganglioside involved in cell migration, the A2B5 epitope,113 revealing a potential
mechanism for its functional effects.
In other studies, Reutter and co-workers investigated whether ManNProp modulates
signaling pathways within oligodendrocytes.114 Treatment of these cells with ManNProp
and the inhibitory neurotransmitter γ-aminobutyric acid (GABA) induced GABA-dependent
oscillations in intracellular calcium. Calcium is an important second messenger in the
nervous system, and calcium oscillations are believed to contribute to a highly plastic
signaling system underlying the communication between neurons and glia.114 Interestingly,
ionotropic GABA receptors are modified by sialic acid,115,116 suggesting that extended N-
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acyl substituents may alter the functional properties of this receptor. However, ManNProp
undoubtedly perturbs the expression of multiple sialylglycoconjugates at the cell surface,
and direct evidence that altered sialylation of the GABA receptor is responsible for the
observed response is lacking. In the future, it will be interesting to uncover the precise
molecular mechanisms by which these modifications to sialic acid structure elicit their
effects on intracellular signaling.
ManNProp has also been shown to promote neuronal growth in various contexts. For
instance, ManNProp induced the neurite outgrowth of small rat CGN, PC12 cells, and chick
DRG neurons.117,118 Moreover, treatment with Man-NProp promoted reestablishment of
functional connections in the perforant pathway, which consists of projections from the
entorhinal cortex into the dentate gyrus of the hippocampus, in coculture experiments.117
Although the particular glycoconjugates responsible for these effects were not elucidated,
several cytosolic proteins implicated in neurite outgrowth were found to be differentially
expressed after the ManNProp treatment, including unc-33 like phosphoprotein (ULIP),
various heat shock proteins, and 14-3-3ε, a protein that associates with both GABA
receptors and the α(2–3)-sialyltransferase IV.117,119,120
Bertozzi and colleagues have explored the influence of various ManNAc derivatives on PSA
biosynthesis. N-Butanoylmannosamine (ManNBut, Figure 5A), but not ManNProp, was
shown to significantly inhibit PSA expression in a dose-dependent manner in the NT2
neuroblastoma cell line. Moreover, both human polysialytransferases responsible for PSA
biosynthesis (STX and PST) displayed reduced kinetic efficiencies for transfer of ManNBut
and ManNPent (Figure 5A), whereas ManNProp was transferred at a rate sufficient for
biosynthesis.118,121 Thus, elongation of the N-acyl side chain of sialic acid may interfere
with recognition of the growing PSA chain by polysialyltransferases. However, findings by
Jennings and co-workers suggest that both ManNBut and ManNProp may be partially
incorporated into sialylglycoconjugates, as detected by flow cytometry using a monoclonal
antibody that recognizes N-propanoyl- and N-butanoyl-PSA.122,123 Consistent with an
inhibitory effect on PSA biosynthesis, ManNBut blocked polysialylation of NCAM in both
chick DRG neurons118 and NT2 cells124 and decreased the outgrowth of DRG neurons.118
The effects on neurite outgrowth were comparable to those elicited by treatment of cells
with endoneuraminidase, an enzyme that cleaves PSA residues.
2.3.4.2. Metabolic Labeling with ManNGcPA: Metabolic labeling of neurons with
unnatural sugars has also been exploited to alter protein recognition events at the cell
surface. Treatment of neuroblastoma–glioma hybrid cells with the sialic acid metabolic
precursor N-glycolylmannosamine pentaacetate (ManNGcPA; Figure 5A) converted cell-
surface sialylglycoconjugates from expressing Neu5Ac to expressing Neu5Gc,125 a sialic
acid form that is not normally found in humans.126 Whereas Neu5Ac sialylglycoconjugates
displayed on neuronal cells bound efficiently to MAG, the binding of MAG to cells
expressing Neu5Gc sialylglycoconjugates was significantly inhibited.127 These studies
demonstrate the potential of metabolic labeling to serve as a useful tool for perturbing
specific glycan–protein interactions.
Murrey and Hsieh-Wilson Page 8













2.3.4.3. Chemoselective Labeling of Sialylated Cell-Surface Glycoconjugates: The
ability to incorporate unnatural sugar analogues into cell-surface glycoconjugates allows for
the introduction of reactive chemical functionalities onto glycoproteins and glycolipids, such
as ketone, azide, or alkyne groups. These functionalities allow for selective labeling of
proteins with reporter groups such as affinity tags and fluorescent dyes or for the delivery of
toxins.128–131 Bertozzi and co-workers have exploited N-levulinoylmannosamine (ManLev),
which contains a ketone functionality appended to the N-acyl side chain (Figure 5A), to
label neuroblastoma cells.129 Incubation of the cells with ManLev resulted in incorporation
of the ketone moiety into sialylated glycans in a concentration-dependent manner.
Subsequent reaction with a biotin hydrazide derivative (Figure 5B) enabled visualization of
sialylglycans by fluorescence microscopy, revealing their presence along the cell body and
neuronal processes.132 Although the specific sialyltransferases involved are not fully
understood, ManLev was successfully incorporated into PSA, suggesting that α(2–8)-
polysialyltransferases are capable of utilizing ketone-modified precursors for PSA
synthesis.132 These studies provide a powerful means to modulate the structure of PSA and
potentially other sialylglycans with a wide variety of chemical groups.
2.3.4.4. Summary of Sialic Acid Metabolic Labeling: Cumulatively, studies have
demonstrated that unnatural ManNAc derivatives can be exploited to manipulate the
structure of sialylated glycans on neuronal cell surfaces. These studies have revealed that
subtle alterations in sialic acid structure can have striking consequences for PSA
biosynthesis and biological phenomena such as neurite outgrowth, cell proliferation, and
migration. In the future, these versatile chemical tools could be employed for visualization
of dynamic neuronal processes in vivo, such as activity-dependent changes in the expression
or localization of sialylglycans. The ability to engineer the glycan composition of cell
surfaces and to selectively label sialylated glycans for imaging or other applications
provides a powerful complementary approach to genetics and biochemistry.
3. α-L-Fucose
3.1. Structure and Biosynthesis
α-L-Fucose (6-deoxy-L-galactose; Fuc) is generally expressed as a terminal monosaccharide
on N- and O-linked glycoproteins and glycolipids. As such, it often serves as an important
molecular recognition element for proteins. Fucose is distinct from other naturally occurring
sugars because it is a deoxyhexose sugar that exists exclusively in the L-configuration
(Figure 6). A structurally diverse array of fucosylated glycans has been identified with
fucose often linked to the C-2, C-3, C-4, or C-6 positions of the penultimate galactose in
glycoconjugates or to the core GalNAc residue of N-linked glycans.1 O-Fucosylation, the
direct modification of serine and threonine residues by fucose, has also been observed on
epidermal growth factor (EGF) repeats of glycoproteins such as Notch, a protein involved in
cell growth and differentiation.133 While fucose is not elongated in N-linked and O-linked
glycans, O-fucose can be elongated by other sugars.1
Given the structural diversity of fucosylated glycans, it is perhaps not surprising that more
than a dozen different human enzymes are involved in the formation of Fuc linkages.1 Two
enzymes, FUT1 and FUT2, are dedicated to the synthesis of Fucα(1–2)Gal glycans, an
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epitope found on the ABO blood group antigens134–136 that has also been implicated in
synaptic plasticity.13,137,138 A gene homologous to FUT1 and FUT2, called Sec1, contains
translational frameshifts and stop codons that interrupt potential open reading frames and
thus appears to be a pseudogene.134 FUT3 catalyzes the synthesis of both α(1–3)- and α(1–
4)-fucosylated glycans and can transfer fucose to both Gal and GlcNAc in an
oligosaccharide chain, whereas FUT4–7 form only α(1–3)-fucosylated glycans.139,140 FUT8
and FUT9 generate Fucα(1–6)GlcNAc structures, with FUT8 generally catalyzing
attachment of this structure to the core asparagine residue of N-linked oligosaccharides141
and FUT9 catalyzing its attachment to a distal GlcNAc of polylactosamine chains.142
FUT10 and FUT11 are putative fucosyltransferases that are reported to synthesize α(1–3)-
fucosylated glycans based on sequence homology, although no functional studies have yet
been performed.1 Finally, POFUT1 and POFUT2, also known as O-fucosyltransferase 1 and
O-fucosyltransferase 2, catalyze the direct fucosylation of serine and threonine residues
within epidermal growth factor repeats.143,144
3.2. Neurobiological Functions
Fucosylated glycans play important roles in various physiological and pathological
processes, including leukocyte adhesion,145,146 host–microbe interactions,147,148 and
neuronal development.149,150 They are prevalent on the glycolipids of erythrocytes, where
they form the ABO blood group antigens that distinguish specific blood types.136 Aberrant
expression of fucosylated glycoconjugates has been associated with cancer,151–154
inflammation,145,155–157 and neoplastic processes.158,159 For instance, the fucosylated
antigens, sialyl LewisX, sialyl LewisY, and sialyl LewisB, are up-regulated in certain cancers
and have been associated with advanced tumor progression and poor clinical
prognosis.160–163 Moreover, deficiency in fucose leads to a congenital disorder of
glycosylation type IIc in humans, also known as leukocyte adhesion deficiency type II (LAD
II). This disorder results in the impairment of leukocyte–vascular epithelium interactions
and is characterized by immunodeficiency, developmental abnormalities, psychomotor
difficulties, and deficits in mental capabilities.164
Although their roles in the brain are less well understood, fucosylated glycans have been
implicated in neural development, learning, and memory. Here, we will highlight aspects of
their biosynthesis and functional roles in the nervous system.
3.2.1. Neuronal Development—Fucose has been reported to play an important role in
neural development. O-Fucosylation is essential for the activity of Notch, a transmembrane
receptor protein that controls a broad range of cell-fate decisions during
development., 165–169 Studies suggest that fucose modulates Notch signaling either by
inducing a conformational change in the protein or by interacting directly with Notch
ligands.168 Notch signaling is believed to be involved in neuronal progenitor maintenance,
and governs the cell-fate decision between neuronal and glial lineages. Notch signaling may
also contribute to the behavior of differentiated neurons and neuronal migration.170 Genetic
deletion of the POFUT1 gene is embryonic lethal in mice and causes developmental defects
similar to those observed upon deletion of Notch receptors, including abnormal
vasculogenesis, somitogenensis, and neurogenesis.171,172 These studies demonstrate the
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importance of fucose in proper neuronal development and implicate Notch fucosylation as
an important mediator of these events.
3.2.2. Learning and Memory—Multiple studies have suggested a role for fucosylation in
learning and memory. For instance, the incorporation of fucose into glycoconjugates in the
brain was significantly enhanced by task-dependent learning in both chicks and rats.173–176
Rats were trained in a brightness discrimination task, in which animals learned to enter a
bright chamber while avoiding a dark one. Trained animals demonstrated an increase in
[3H]-labeled fucose incorporation into glycoconjugates at synapses, the specialized sites of
communication between neurons.175 Moreover, exogenous application of L-fucose or 2′-
fucosyllactose (Figure 6) enhanced long-term potentiation (LTP), an electrophysiological
model for learning and memory, both in vivo and in hippocampal slices.177,178
Fucose is highly enriched at neuronal synapses,13,179,180 where the majority of the
fucosylated glycoconjugates exist as complex N-linked structures.181 Studies indicate that
the activity of fucosyltransferases increases during synaptoge-nesis182 and upon passive-
avoidance training in animals.183 Moreover, the cellular machinery involved in protein
glycosylation can be found within dendrites,184,185 raising the intriguing possibility that
local protein synthesis and fucosylation may be occurring at synapses in response to
neuronal stimulation.
Further studies have specifically implicated Fucα(1–2)Gal linkages in neuronal
communication processes. For instance, 2-deoxy-D-galactose (2-dGal; Figure 6), which
competes with native galactose for incorporation into glycan chains and thus prevents the
formation of Fucα(1–2)Gal linkages,186 has been shown to induce reversible amnesia in
animals.138,186,187 In contrast, other small molecule sugars such as 2-deoxy-D-glucose, Gal,
or Glc had no effect, suggesting a unique function for Fucα(1–2)Gal saccharides. 2-dGal has
also been reported to interfere with the maintenance of LTP, both in vitro and in vivo.188,189
Furthermore, a monoclonal antibody specific for Fucα(1–2)Gal190 significantly impaired
memory formation in animals, presumably by blocking formation of the Fucα(1–2)Gal
epitope.137
3.3. Chemical Approaches for Studying L-Fucose
Despite intriguing evidence linking Fucα(1–2)Gal sugars to neuronal communication and
memory storage, the molecular mechanisms by which these sugars exert their effects are not
well understood. Recently, however, chemical tools have been developed that are beginning
to shed light on the roles of Fucα(1–2)Gal lectins and glycoproteins in the brain.
3.3.1. Deoxygalactose Analogues—Hsieh-Wilson and co-workers investigated the
effects of the amnesic compound 2-dGal and other fucosylation inhibitors on cultured
hippocampal neurons. Inhibition of Fucα-(1–2)Gal linkages using 2-dGal led to stunted
neurite outgrowth in young neurons lacking functional synapses (Figure 7).14 In contrast, 3-
deoxy-D-galactose (3-dGal), which inhibits fucose incorporation at the C-3 position of
galactose, had no effect on neurite growth, suggesting that specific fucose linkages are
important for the neuritogenic activity. The effects of 2-dGal could be successfully rescued
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by the addition of excess D-Gal to the media, suggesting that the inhibition can be reversed
by the de novo synthesis of Fucα(1–2)Gal sugars.
Interestingly, 2-dGal also exerted dramatic effects on the morphology of older neurons, even
after axonal differentiation and synaptogenesis had begun to occur.13 Application of 2-dGal
led to a remarkable retraction of dendrites and collapse of synapses, whereas 6-dGal had no
effect. However, D-Gal was only partially able to rescue the effects of 2-dGal, which may
reflect the decreased plasticity of older neurons. Thus, fucosylated glycans and, in particular,
Fucα(1–2)Gal glycoconjugates appear to be important for modulating neuronal morphology
and maintaining functional neuronal connections.
To gain insight into the molecular mechanisms involved, Hsieh-Wilson and co-workers
sought to identify Fucα(1–2)Gal glycoproteins in the hippocampus.13 Using a gel-based
mass spectrometry approach, they identified synapsins Ia and Ib as the predominant
Fucα(1–2)Gal glycoproteins in older hippocampal cultures and in the adult rat brain. The
synapsins are synaptic vesicle-associated proteins that play important roles in
neurotransmitter release and synaptogenesis.191,192 Fucosylation of synapsin I was found to
have significant effects on synapsin expression in neurons, protecting it from proteolytic
degradation by the calcium-activated protease calpain. Moreover, studies using 2-dGal and
synapsin I-deficient mice showed that synapsin fucosylation contributes to the profound
effects of 2-dGal on neurite outgrowth and synapse formation. However, other unknown
Fucα(1–2)Gal glycoproteins were also involved in the process. These studies provide the
first evidence that Fucα(1–2)Gal glycoproteins are directly involved in neurite outgrowth
and underscore the importance of identifying the Fucα(1–2)Gal proteome of the brain.
3.3.2. Glycopolymers and Imaging Probes—Fucose often occupies a terminal
position on glycan chains, and as such, it serves as an important molecular recognition
element for lectins. A well-studied example is the binding of L-selectin to the fucosylated
glycan sialyl LewisX, an interaction known to be critical for leukocyte adhesion.1 To
investigate whether Fucα(1–2)Gal lectins exist in the mammalian brain, a small molecule
probe was designed and synthesized that contained the Fucα(1–2)Gal epitope and a biotin
moiety for imaging potential lectin receptors in the brain (Figure 8).14 Rat hippocampal
neurons were incubated with the small molecule probe, and the bound probe was visualized
on the cells using a streptavidin–dye conjugate (Figure 8). Strong fluorescent staining of the
cell body and neuronal processes was observed, consistent with the presence of fucose-
binding lectin receptors.
To investigate whether the association of Fucα(1–2)Gal with these receptors would elicit a
neuronal response, Hsieh-Wilson and colleagues treated cultured neurons with poly-
acrylamide-based polymers displaying multiple copies of the Fucα(1–2)Gal epitope.14 The
Fucα(1–2)Gal polymers promoted neurite outgrowth by more than 75%, and the potency of
the compounds was dramatically enhanced with increasing polymer concentration or
carbohydrate valency. Importantly, polymers bearing other carbohydrates moieties, such as
GlcNAc, Gal, Fucα(1–3)GlcNAc, or only Fuc, had no appreciable effects, indicating that
the observed neuritogenic activity was specific for Fucα(1–2)Gal. Together, these studies
provide the first evidence that Fucα(1–2)Gal lectin receptors are found in the brain, and they
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identify a novel carbohydrate-mediated pathway for the regulation of neuronal growth. This
work also highlights the power of chemical probes to explore the biological effects of
specific glycans and their associated receptors. It will be important in the future to identify
the lectins involved and to elucidate the specific mechanisms and pathways leading to
neuronal growth.
3.3.3. Metabolic Labeling Using Alkynyl or Azido Fucose Analogues—Recently,
the Bertozzi and Wong groups independently demonstrated that alkynyl- or azido-containing
fucose analogues could be exploited to selectively label and image fucosylated glycans in
mammalian cells.193,194 Their strategy exploits the fucose salvage pathway to convert
unnatural fucose sugars into the corresponding GDP-fucose analogues, which then serve as
donors for fucosyltransferases. Once the azido or alkynyl fucose analogue is incorporated
into glycans, it can be reacted with fluorescent dyes, biotin, or peptides via Staudinger
ligation or [3 + 2] azide–alkyne cycloaddition chemistry. Bertozzi and co-workers
synthesized fucose derivatives with azido groups at the C-2, C-4, and C-6 positions.193 Only
the C-6 azido fucose analogue (Figure 6) was successfully incorporated into the glycans of
the Jurkat T lymphocyte cell line, consistent with earlier observations that some
fucosyltransferases tolerate substitutions at the C-6 position of the pyranose ring. Wong and
colleagues demonstrated that both azido- and alkynyl-modified fucose derivatives (Figure 6)
could be incorporated into the glycans of hepatoma cells, allowing for fluorescent imaging
of fucosylated glycoconjugates.194,195 Interestingly, the alkynyl fucose analogue was shown
to be significantly less toxic to cells than the azido fucose analogue.194 Future application of
these powerful approaches to neurons should facilitate proteomic studies to identify
fucosylated glycoproteins and may allow for the dynamic imaging of protein fucosylation in
vivo.
3.3.4. Summary of Fucosyl Oligosaccharides—Cumulatively, studies using
chemical probes have revealed a role for fucosyl oligosaccharides and their associated
lectins and glycoproteins in the regulation of neurite growth and synapse formation. These
findings may shed light on behavioral and electrophysiological studies implicating Fucα(1–
2)Gal in long-term memory storage. Alterations in neuronal morphology, such as dynamic
changes in dendritic spine number and shape, occur during memory consolidation and
LTP.196,197 One possibility is that the interaction between certain Fucα(1–2)Gal
glycoproteins and lectins may promote the stabilization of synaptic connections that underlie
learning and memory. In addition, fucosylation may exert its effects independently of
lectins, by stabilizing fucosylated glycoproteins such as synapsin or modulating their
functions. The continued development and application of chemical tools has tremendous
potential to expand our understanding of the roles of fucosylated lectins and glycoproteins in
the brain and may provide exciting opportunities to modulate neuronal communication
processes.
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4.1. Structure and Biological Functions
O-GlcNAc glycosylation is the covalent attachment of β-N-acetylglucosamine to serine and
threonine residues of proteins (Figure 9). Unlike other forms of glycosylation, O-GlcNAc is
a dynamic, reversible modification found only on intracellular proteins, rendering it akin to
protein phosphorylation. A wide range of proteins are O-GlcNAc-modified, including
transcription factors, nuclear pore proteins, cytoskeletal proteins, and synaptic
proteins.8,12,198,199–202 Several excellent reviews have described the functional roles of O-
GlcNAc in transcription,203 apoptosis,204,205 signal transduction,199 nutrient sensing,206,207
and proteasomal degradation.206 O-GlcNAc glycosylation has also been implicated in the
cellular stress response208,209 and is induced by oxidative, osmotic, metabolic, and chemical
stress.8,206 Levels of O-GlcNAc glycosylation are altered in disease states such as cancer,
diabetes, and Alzheimer’s disease.201,204,207,210–215 Moreover, one of the hallmarks of
Alzheimer’s disease is the formation of neurofibrillary tangles by hyperphosphorylated tau
protein,216 and several studies suggest that O-GlcNAc glycosylation negatively regulates the
ability of tau to become phosphorylated.217,218 Thus, the investigation of O-GlcNAc
function may provide insights into our understanding of critical cellular processes and
diseases.
4.2. Neurobiological Functions of O-GlcNAc
Emerging evidence indicates an important role for O-GlcNAc glycosylation in the nervous
system. The enzymes that catalyze the addition and removal of O-GlcNAc, O-GlcNAc
transferase (OGT) and O-GlcNAcase (OGA), are most highly expressed in the brain219 and
are enriched in both pre- and postsynaptic nerve terminals.220 OGT expression is critical for
cell survival,221 and neuronal-specific deletion of the OGT gene in mice leads to abnormal
development, defects in motor coordination, and early neonatal death.222 Thus far, more
than 50 neuronal proteins have been shown to be O-GlcNAc-modified, including proteins
involved in transcription (e.g., CREB (cAMP-response element binding-protein), Sox2
(SRY box-containing gene 2), ATF-2 (activating transcription factor-2)), neuronal signaling
(synGAP (synaptic Ras GTPase activating protein)), bassoon, the guanine nucleotide
exchange factor PDZ-GEF, and synapsin I), synaptic plasticity (synaptopodin and δ-
catenin), and neurodegenerative disease (tau and APP (β-amyloid precursor
protein)).8,202,217,223–227 Finally, O-GlcNAc glycosylation levels are dynamically
modulated by excitatory stimulation of the brain in vivo and upon activation of specific
kinase pathways in cultured cerebellar neurons.223
Despite its importance, the functional roles of O-GlcNAc glycosylation are only beginning
to be understood in the brain. A major challenge has been the difficulty of detecting and
studying the modification in vivo. Similar to phosphorylation, O-GlcNAc is often dynamic,
substoichiometric, targeted to subcellular compartments, and prevalent on low abundance
regulatory proteins. The sugar is also both enzymatically and chemically labile. For
example, mass spectrometry analyses to identify O-GlcNAc-modified proteins and map
glycosylation sites are challenged by loss of the modification upon collision-induced
dissociation (CID). The lack of a well-defined consensus sequence for OGT has precluded
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the determination of in vivo glycosylation sites based on primary sequence alone.
Furthermore, the complexity of the nervous system and its unique technical challenges (e.g.,
postmitotic cells, multiple cell types, blood–brain barrier, complex organization) greatly
complicates efforts to study O-GlcNAc glycosylation and necessitates the development of
rapid, highly sensitive detection methods. Here, we describe chemical approaches
undertaken to overcome these challenges and highlight how they have advanced our
understanding of the roles of O-GlcNAc glycosylation in neuronal function and dysfunction.
4.3. Chemical Tools To Study O-GlcNAc Glycosylation
4.3.1. Chemoenzymatic Labeling of O-GlcNAc Proteins
4.3.1.1. Rapid, Sensitive Detection: Traditional methods for detecting O-GlcNAc-modified
proteins often suffer from limited sensitivity and specificity. For instance, radiolabeling of
the proteins using UDP-[3H]-galactose and β(1–4)-galactosyltransferase (GalT), an enzyme
that transfers [3H]-galactose onto terminal GlcNAc groups of glycoproteins,228 can require
weeks for visualization and lacks the sensitivity to detect certain O-GlcNAc-modified
proteins. Lectins228 and antibodies229,230 are also effective methods, but they bind only a
subset of the O-GlcNAc-modified proteins (usually those with multiple glycosylation sites)
and have limited affinity and specificity.
In response, a chemoenzymatic approach for tagging O-GlcNAc proteins was developed by
Hsieh-Wilson and coworkers that allows for more rapid and sensitive detection. An
unnatural substrate for GalT was designed, in which a bioorthogonal ketone moiety was
appended to the C-2 position of galactose (UDP-ketogalactose probe, Figure 10A).231
Studies by Qasba and colleagues had demonstrated that a mutant form of GalT (Y289L)
tolerates minor substitutions at this position.232 Once transferred, the ketone moiety can be
reacted with an aminooxy biotin derivative, thus permitting the sensitive detection of O-
GlcNAc-modified proteins by chemiluminescence.231 Notably, this method enables the
identification of O-GlcNAc-glycosylated proteins that elude detection using other methods.
For example, detection of the glycoproteins α-crystallin and CREB was accomplished
within minutes, whereas lectins and antibodies failed to detect the modification on these
proteins and tritium labeling required more than a week to develop.231 Thus, this
chemoenzymatic approach provides superior sensitivity relative to traditional methods and
accelerates the identification of new O-GlcNAc-modified proteins.
4.3.1.2. Identification of O-GlcNAc-Glycosylated Proteins from Cells: Selective
biotinylation of proteins using the chemoenzymatic approach also facilitates the parallel
purification of O-GlcNAc-modified proteins from cell or tissue extracts by affinity
chromatography.233 Previous methods have necessitated purification of individual proteins
prior to analysis, a tedious and time-consuming process. Using the chemoenzymatic
approach, the tagged O-GlcNAc proteins can be isolated in a single step by streptavidin
affinity chromatography and interrogated for modification in parallel by Western
blotting.233 This strategy was used to demonstrate that the AP-1 transcription factors c-Fos
and c-Jun, as well as the activating transcription factor ATF-1, are O-GlcNAc-modified in
HeLa cells.233 In addition, the identification of O-GlcNAc on CREB-binding protein (CBP)
reveals a new class of O-GlcNAc-glycosylated proteins, the histone acetyltransferases
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(HAT). Thus, glycosylation can be readily investigated across structurally or functionally
related proteins, as well as novel functional classes. Together, studies have revealed that a
broad number of transcriptional components are O-GlcNAc-glycosylated,202,223,233 and O-
GlcNAc may function as a general regulatory modification for the control of
transcription.239,240
4.3.1.3. Proteome-Wide Analyses: When used in conjunction with high-throughput mass
spectrometry, the chemoenzymatic approach can be exploited for proteome-wide analyses of
O-GlcNAc-modified proteins.202 Proteins from cell lysates are chemoenzymatically labeled
and pro-teolytically digested. The desired glycopeptides are then captured by avidin affinity
chromatography and analyzed by HPLC in line with tandem mass spectrometry (LC–MS/
MS). The ketogalactose–biotin tag facilitates the isolation of O-GlcNAc glycopeptides from
complex mixtures. This enrichment step is often crucial for detecting low-abundance post-
translational modifications. The tag also provides a unique signature on the mass
spectrometer, thus enabling unambiguous identification of O-GlcNAc-modified peptides and
mapping of glycosylation sites to specific functional domains within a protein. Using this
approach, Hsieh-Wilson, Peters, and colleagues reported the first proteome-wide
identification of O-GlcNAc-modified proteins from the mammalian brain.202 Nearly 100
peptides were identified containing the mass spectrometry signature, and 34 of these
peptides were successfully sequenced. The sequenced peptides identified 25 different
proteins from rat brain. Of the proteins identified, only two proteins had been previously
reported, and 23 were novel O-GlcNAc-glycosylated proteins, thus significantly expanding
the repertoire of proteins known to be modified.
This method demonstrates the power of chemical-tagging approaches to accelerate the high-
throughput identification of O-GlcNAc glycoproteins. Notably, many of the proteins
identified have important functional roles in gene regulation, cytoskeletal dynamics,
neuronal signaling, and synaptic plasticity. For example, synaptopodin, synGap, and shank2
(SH3 and multiple ankyrin repeat domains protein 2) are critical for the regulation of
dendritic spine formation.234–236 Synaptopodin and δ-catenin have important roles in
learning and memory,234,237 and the guanine nucleotide exchange factor PDZ-GEF is
involved in the assembly of signal transduction complexes at the synapse.238 Together, these
studies suggest that O-GlcNAc glycosylation may play a role in mediating neuronal
communication and signaling networks. Consistent with this observation, Burlingame and
coworkers recently employed lectin weak-affinity chromatography in conjunction with mass
spectrometry to identify 18 O-GlcNAc-glycosylated proteins from the postsynaptic density
fraction of rat brain.224 The proteins represent multiple functional classes, and several
proteins involved in synaptic vesicle cycling were found to be extensively O-GlcNAc-
glycosylated, such as bassoon, piccolo, and synapsin I.224
While the chemoenzymatic approach has broad application to the study of O-GlcNAc-
glycosylated proteins from cell and tissue extracts, O-GlcNAc proteins cannot be labeled in
animals using this method. In addition, the determination of exact glycosylation sites is still
difficult, because the ketogalactose–biotin moiety can be lost upon CID in the mass
spectrometer. Instead, O-GlcNAc modification sites are mapped to short amino acid
sequences within proteins, which still provides insight into the function of the modification.
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Despite these limitations, the chemoenzymatic labeling strategy is so powerful for in vitro
analysis and proteomics that a variation of this approach is now commercially available for
fluorescent labeling or biotinylation of O-GlcNAc-glycosylated proteins using [3 + 2]
cycloaddition chemistry (Figure 10B).
4.3.2. Metabolic Labeling of O-GlcNAc Proteins
4.3.2.1. Incorporation of GlcNAz into O-GlcNAc Proteins: A complementary strategy
that enables tagging of O-GlcNAcylated proteins in living cells involves metabolically
labeling the proteins with unnatural GlcNAc derivatives. Bertozzi and colleagues
demonstrated that N-(2-azidoacetyl)-glucosamine (GlcNAz, Figure 10C) is processed by
enzymes in the hexosamine salvage pathway, resulting in incorporation of a bioorthogonal
azide functionality into O-GlcNAc-glycosylated proteins.241 The azido group can be
subsequently labeled with triarylphosphines via the Staudinger ligation. Using this approach,
the authors demonstrated successful incorporation of GlcNAz into both nuclear and
cytoplasmic proteins of cultured Jurkat T lymphocyte cells. In particular, selective labeling
and detection of the nuclear pore protein p62, a known O-GlcNAc-modified protein with
>10 glycosylation sites,242 was shown using a phosphine–FLAG probe. Although
incomplete labeling of O-GlcNAc-glycosylated proteins limits the sensitivity of this
approach relative to the chemoenzymatic strategy described above, metabolic labeling with
GlcNAz sugars can be performed in living cells and might allow for the dynamic imaging of
O-GlcNAc-glycosylated proteins in vivo.
4.3.2.2. Proteomic Analysis by Metabolic Labeling: Although metabolic labeling has not
yet been applied to neurons, it represents another powerful chemical approach for the high-
throughput identification of O-GlcNAc-modified proteins. Zhao and colleagues labeled O-
GlcNAc proteins in the HeLa cervical cancer cell line with GlcNAz and tagged them with a
biotin phosphine reagent (Figure 10C).243,244 Tryptic digestion of the affinity-captured
proteins, followed by LC–MS/MS analysis, led to the identification of 199 putative O-
GlcNAc-modified proteins. Because the presence of the GlcNAc moiety was inferred rather
than detected directly, independent confirmation of the modification by immunoblotting was
required and demonstrated on 23 of the 199 proteins.
While this method provides a powerful chemical tool for profiling O-GlcNAc-modified
proteins, there are some limitations of this procedure for in vivo labeling in the brain. Most
sugars do not cross the blood–brain barrier,245 and thus in vivo labeling with these
molecules would entail invasive surgical procedures for intracranial administration rather
than simple intraperitoneal injection. In addition, metabolic labeling is not quantitative,
which may limit the sensitivity of detection as well as preclude the ability to monitor
glycosylation dynamics. Despite these limitations, the approach has been successfully
employed to investigate the O-GlcNAc proteome in both mammalian and insect cell
lines.243,244 In the future, metabolic labeling could prove a useful tool for studying the O-
GlcNAc proteome in cultured neurons.
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4.3.3. Methods for Mapping Exact Glycosylation Sites
4.3.3.1. The β-Elimination Followed by Michael Addition with Dithiothreitol (BEMAD)
Approach: The identification of O-GlcNAc modification sites within proteins is critical for
elucidating the functions of O-GlcNAc in specific biological contexts. Nonetheless, the
exact sites of glycosylation remain unknown for most proteins. Mapping glycosylation sites
has been challenging due to the low abundance of the modification and the lability of the
glycosidic linkage during fragmentation on a mass spectrometer, which can result in the loss
of direct amino acid identification. Hart and co-workers showed that the labile GlcNAc
moiety could be replaced with a more stable sulfide adduct by alkaline-induced β-
elimination followed by Michael addition with dithiothreitol (BEMAD, Figure 11).246 The
resulting sulfide adduct is not cleaved upon CID, thereby allowing sites of glycosylation to
be more readily determined. However, a limitation of this approach is that it is often
destructive to proteins,247,248 and selectivity controls must be performed to distinguish
among O-GlcNAc, O-phosphate, and other O-linked carbohydrates.246 When biotin
pentylamine is used in place of dithiothreitol, O-GlcNAc-modified peptides can be
selectively biotinylated, enriched by affinity chromatography, and identified by LC–MS/MS
analysis. This method has been successfully employed to identify novel O-GlcNAc sites on
purified glycoproteins such as synapsin I and proteins from a purified rat brain nuclear pore
complex.246 Further extension of BEMAD to complex mixtures for the high-throughput
mapping of O-GlcNAc sites is an important future goal.
4.3.3.2. Electron Transfer Dissociation (ETD) and Electron Capture Dissociation
(ECD) Coupled with Lectin Affinity Chromatography or Chemoenzymatic Labeling:
Recently, the development of novel fragmentation methods for mass spectrometry has
facilitated the identification of O-GlcNAc modification sites. Electron transfer dissociation
(ETD) and electron capture dissociation (ECD) use thermal electrons to produce sequence
specific-peptide fragmentation without the loss of labile post-translational modifications
such as O-GlcNAc and O-phosphate.249 ECD has recently been used by Burlingame and co-
workers to identify O-GlcNAc glycosylation sites following enrichment of the modified
peptides by lectin weak-affinity chromatography.224 The authors were able to identify
glycosylation sites on several neuronal proteins such as spectrin β2, shank2, bassoon, and
piccolo.
While ECD requires the use of a Fourier transform mass spectrometer, ETD has the
advantage of being performed in appropriately modified ion trap mass spectrometers,
rendering the technology powerful and more accessible. Hsieh-Wilson, Coon, and
colleagues have implemented ETD fragmentation to map glycosylation sites on neuronal
proteins following chemoenzymatic labeling and enrichment by avidin affinity
chromatography. The authors identified glycosylation sites on multiple proteins such as the
neuron-specific transcriptional repressor BHC80, the transcriptional repressor p66β, the
transcriptional coactivator SRC-1, and the zinc finger RNA-binding protein.223 With further
methodological refinements and advances in database search algorithms for fragment ions, it
is anticipated that ETD and ECD will become increasingly powerful tools for the study of
O-GlcNAc glycosylation.
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4.3.4. Monitoring O-GlcNAc Dynamics—Unlike most forms of protein glycosylation,
O-GlcNAc glycosylation is reversible and dynamic. Several studies have shown that global
O-GlcNAc levels in cells change within minutes of activation by specific extracellular
stimuli.250,251 O-GlcNAc levels are also highly responsive to cellular glucose
concentrations, as approximately 2–5% of all glucose is metabolized through the
hexosamine biosynthesis pathway to generate UDP-GlcNAc.252–254 Furthermore, studies
have suggested a potential interplay between O-GlcNAc glycosylation and phosphorylation
in neurons. An inverse relationship between O-GlcNAc and O-phosphate was observed
upon activation of protein kinase C (PKC) or cAMP-dependent protein kinase (PKA) in the
cytoskeletal protein fraction of cultured cerebellar neurons.255 As described below, recent
quantitative proteomics studies have shown that O-GlcNAc glycosylation is dynamically
induced by excitatory stimulation of the mammalian brain in vivo.223 Finally, O-GlcNAc
glycosylation is known to be dysregulated in multiple disease states and is believed to
contribute to the etiology of certain diseases, such as diabetes, Alzheimer’s disease, and
cancer.207,252,256,257
Despite considerable investigation, the specific proteins undergoing dynamic changes in
glycosylation remain largely unknown. Moreover, the molecular mechanisms and signaling
pathways involved in the regulation of OGT and OGA are poorly understood. As such, there
is a great need to develop chemical tools to monitor changes in glycosylation on specific
proteins and at specific modification sites in both normal and disease states. We describe
below some of the chemical approaches that have been developed to address these
challenges.
4.3.4.1. FRET-Based Sensors: Mahal and colleagues developed a fluorescence resonance
energy transfer (FRET)-based sensor to investigate O-GlcNAc glycosylation dynamics in
living cells.258 Their approach uses two fluorophores, enhanced cyan and yellow fluorescent
protein, separated by a known OGT substrate domain and the bacterial O-GlcNAc lectin
GafD (Figure 12). Upon O-GlcNAc glycosylation of the substrate domain, the GafD domain
binds the carbohydrate moiety, bringing the fluorophores into close proximity and leading to
a concomitant increase in FRET. The authors detected a significant increase in FRET from
HeLa cells transfected with the sensor construct upon treatment with glucosamine or the
OGA inhibitor PUGNAc (O-(2-acet-amido-2-deoxy-D-glucopyranosylidene)amino-N-
phenylcarbamate, Figure 14). 258 This biological sensor represents a promising tool for the
investigation of O-GlcNAc glycosylation dynamics in response to a variety of cellular
stimuli.
4.3.4.2. The Quantitative Isotopic and Chemoenzymatic Tagging(QUIC-Tag)Approach
for Quantitative Proteomics: Hsieh-Wilson, Peters, and co-workers developed a method to
probe dynamic changes in O-GlcNAc glycosylation using quantitative mass spectrometry-
based proteomics.223 Their QUIC-Tag approach (quantitative isotopic and chemoenzymatic
tagging) involves chemoenzymatically labeling proteins from two different cell states (e.g.,
normal versus diseased; stimulated versus unstimulated) with the keto-galactose–biotin
group as described above (Figure 13).223 After proteolytic digestion, the resulting peptides
are isotopically labeled with either heavy or light isotope tags using reductive amination
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chemistry to distinguish the two populations. The peptides are subsequently combined, and
the biotinylated O-GlcNAc peptides are captured using avidin chromatography. MS analysis
reveals two ions for each glycosylated peptide (corresponding to each of the two isotopically
labeled forms), and calculation of the peak areas measures the change in glycosylation level
for each peptide. Importantly, as the observed peptides are sequenced using CID or ETD
MS, the method identifies specific proteins undergoing dynamic changes in glycosylation
and can be used to monitor changes at particular glycosylation sites within proteins.
This approach has advantages over other methods of O-GlcNAc detection. For instance,
lectins and O-GlcNAc antibodies are typically used to detect only global changes in O-
GlcNAc glycosylation by Western blotting and do not monitor individual glycosylation
sites. Metabolic labeling using GlcNAz may alter the kinetic efficiency of O-GlcNAc
transfer to protein substrates, as well as influx through the hexosamine biosynthesis
pathway, which complicates efforts to quantify dynamic changes in response to cellular
stimuli. In contrast, the QUIC-Tag approach is performed on denatured protein lysates and
thus preserves the physiological glycosylation state of the protein without perturbing intra-
cellular glycosylation pathways.
By this approach, O-GlcNAc glycosylation was found to be stimulated upon PUGNAc
treatment of cortical neurons or kainic acid-induced excitatory stimulation of rodent brains
in vivo.223 Robust changes in O-GlcNAc glycosylation were observed at specific sites on
several proteins, whereas other modification sites remained unchanged, suggesting that O-
GlcNAc is subject to complex regulation in neurons. For example, glycosylation of early
growth response-1 (EGR-1), a transcription factor involved in long-term memory formation
and cell survival,259,260 increased greater than 10-fold after kainic acid stimulation. Because
the dynamic glycosylation site within EGR-1 lies within its transactivation domain, O-
GlcNAc glycosylation may modulate the transcriptional activity of EGR-1 and modulate
gene expression. Cumulatively, these studies indicate that O-GlcNAc glycosylation is
reversible, subject to complex regulation, and induced by neuronal activity, which supports
the notion that O-GlcNAc represents an important regulatory modification in the brain.
4.3.4.3. Stable Isotope Labeling with Amino Acids in Cell Culture(SILAC)Coupled
with Affinity Chromatography: Recently, Hart and co-workers employed the SILAC
(stable isotope labeling with amino acids in cell culture) method for quantitative
proteomics261 in conjunction with immunoaffinity chromatography to investigate the
interplay between O-GlcNAc and phosphorylation in COS-7 kidney fibroblast cells.262 Cells
from two different states were labeled with either heavy or light isotopes of arginine and
combined. Proteins of interest were subsequently isolated by affinity chromatography using
a general O-GlcNAc antibody, resolved by SDS–PAGE, proteolytically digested, and
analyzed by LC–MS/MS.
Using this approach, Hart and colleagues investigated the effects of lithium inhibition of
glycogen synthase kinase-3 (GSK-3) on O-GlcNAc glycosylation levels. GSK-3 is involved
in multiple intracellular signaling cascades and is implicated in the etiology of Alzheimer’s
disease, diabetes, and bipolar disorder, thus making it a desirable therapeutic target.263,264
The authors identified 10 proteins that were enriched after LiCl treatment, suggesting that
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they underwent increases in O-GlcNAc glycosylation. The increases in glycosylation were
confirmed on four proteins by immunoprecipitation. Interestingly, many proteins exhibited
no change, and 19 proteins showed decreases in glycosylation. These studies suggest that a
complex interplay exists between O-phosphate and O-GlcNAc within signaling networks.
Although this approach works well for dividing cells, SILAC is not amenable to tissues and
quiescent cells such as neurons. In addition, the method does not readily enable direct
detection of the O-GlcNAc modification, and thus independent confirmation by
immunoprecipitation is required. Nonetheless, this approach provides another powerful
strategy to investigate the cellular dynamics of O-GlcNAc glycosylation.
4.3.4.4. Small-Molecule Inhibitors of OGT and OGA: Traditional genetic approaches
have revealed insights into the functions of OGT and OGA in vivo. For example, genetic
deletion of the OGT gene in mice has revealed that OGT is critical for cell survival, and
neuron-specific deletion of OGT results in defects in mouse embryogenesis, loss of
locomotor control, and neonatal death.221,222 Although such studies have revealed an
important role for these enzymes in neural development, investigations into the functions of
O-GlcNAc remain challenging, particularly in adult animals. The development of small-
molecule inhibitors for OGT and OGA has been actively pursued to enable direct temporal
and spatial control over OGT and OGA activity.
Well-known small-molecule inhibitors of OGT such as alloxan (Figure 14) show multiple
nonspecific effects such as inhibition of OGA and glucokinase,265,266 as well as formation
of superoxide radicals.267 To develop better pharmacological agents, Walker and co-workers
screened a library using a high-throughput, fluorescence-based assay and identified several
novel compounds that inhibited OGT activity in vitro.268 Notably, the compounds
selectively inhibited OGT but not MurG, a related enzyme that also uses UDP-GlcNAc as a
substrate.
As PUGNAc, the most commonly used OGA inhibitor, suffers from nonspecific activity
toward β-hexosaminidase,269 several groups are working to develop more selective
inhibitors. The Vocadlo and Hanover groups have extended the N-acyl substituent of
PUGNAc to generate inhibitors with 10-fold selectivity for OGA over β-
hexosaminidase.269,270 van Aalten and colleagues developed a nagstatin derivative based the
crystal structure of a bacterial OGA (Figure 14).271 This molecule contains an
isobutanamido group at the N8 position that improves selectivity by fitting into a pocket of
the enzyme and a phenethyl group at the C2 position that interacts with a solvent-exposed
tryptophan from bacterial OGA. More recently, the Hanover and Vocadlo groups
independently developed novel OGA inhibitors based on the nonspecific hexosaminidase
inhibitor GlcNAc-thiazaoline, by adding fluoro, azido, or alkyl substituents (Figure 14). The
resultant inhibitors exhibited over 3000-fold selectivity for OGA over β-
hexosaminidase.272,273
The development of such compounds may enable the selective inhibition of OGT and OGA
in cultured neurons, as well as in vivo. The ability to perturb O-GlcNAc enzymes and
glycosylation levels with small molecules should reveal new information about the
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functional roles of O-GlcNAc glycosylation in the nervous system, as well as facilitate the
identification of signaling pathways that regulate OGT and OGA.
5. Glycosaminoglycans
5.1. Structure and Diversity
Glycosaminoglycans (GAGs) are sulfated, linear polysaccharides that represent a central
component of the extracellular matrix (ECM) and are involved in a myriad of biological
functions, including blood coagulation,274,275 angiogene-sis,276–278 tumor growth and
metastasis,279–281 neurite outgrowth,282–285 spinalcordinjury,286–288
anddevelopment.289–291 They are composed of repeating disaccharide units containing a
hexuronic acid sugar linked to a hexosamine sugar.292,293 There are several classes of GAGs
(Figure 15), each of which are distinguished by backbone composition, including heparin
and heparan sulfate (HS), chondroitin sulfate (CS), dermatan sulfate (DS), keratan sulfate
(KS), and hyaluronic acid (HA). Heparin and HS contain D-glucosamine (GlcN) and either
D-glucuronic acid (GlcA) or L-iduronic acid (IdoA) connected by α(1–4) and β (1–4)
linkages. In contrast, CS polymers contain N-acetylgalactosamine (GalNAc) instead of
GlcNAc in alternating β (1–3) and β (1–4) linkages to GlcA, whereas DS polymers have
both GlcA and IdoA linked to GalNAc. Heparin/HS and CS/DS are attached to proteins
through O-linkages to serine residues via a GlcAβ (1–3)Gal-β (1–3)Galβ (1–4)Xyl (Xyl =
xylose) tetrasaccharide linker, forming glycoconjugates known as proteoglycans.294–296 KS
is attached to proteoglycans through either N- or O-linkages. Hyaluronic acid is unique in
that it is not protein-bound and is reportedly synthesized in the plasma membrane,296,297
whereas proteoglycans are synthesized in the Golgi apparatus.292,293
In addition to having different backbone compositions, GAGs display remarkable structural
variation through sulfation of various hydroxyl groups along the polysaccharide backbone
(Figure 15). The sulfation patterns of GAGs are incredibly diverse, owing to the large
number of potential sulfation sites and possible combinations of differentially sulfated
disaccharides linked in tandem. For example, heparin and HS disaccharide units can be
sulfated at the C-2 position of IdoA or the C-3 and C-6 positions of GlcN. The C-2 amine of
GlcN can also be acetylated, sulfated, or unmodified. Similarly, CS can be sulfated at the
C-4 and C-6 positions of GalNAc, as well as the C-2 and C-3 positions of GlcA. A simple
HS disaccharide has 48 potential sulfated sequences, yielding tetrasaccharides with over
2300 possible sulfation sequences.
GAGs also vary in chain length from ~10 to 200 disaccharide units, with clusters of low and
high sulfation along the polysaccharide backbone.298 Structural studies suggest that GAGs
can adopt a variety of helical conformations, such as variance in helical pitch that may
depend on the associated counterion.299,300 Further structural diversity is obtained from the
conformational flexibility of the pyranose ring of IdoA, which exists in equilibrium between
the chair and skew-boat conformations when sulfated at the C-2 position.298 Thus, the
combination of different sequences, charge distributions, and conformations gives rise to
tremendous chemical and structural diversity within glycosaminoglycan chains.
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5.2.1. Neuronal Development—Evidence from genetic and biochemical approaches
suggests that the sulfation patterns of GAGs are important for modulating their biological
activity and can exert profound effects on organismal development. For instance, mutation
of the N-deacetylase–N-sulfotransferase gene (Ndst-1) involved in HS biosynthesis inhibits
growth factor signaling that disrupts normal embryonic development in Drosophila.290 HS
and CS have been shown to interact with numerous growth factors and axon guidance
proteins in a sulfation-specific manner.283,301–308 Moreover, the sulfation patterns of HS
and CS change during the course of brain development,309,310 and specific CS sulfation
patterns are differentially expressed in certain brain regions.311,312 The sulfation patterns of
HS and CS are also organ- and age-specific, as is the expression of different
sulfotransferases.309,310 Thus, HS and CS sulfation patterns in the brain are tightly regulated
with the exquisite spatial and temporal control required for neuronal development.
5.2.2. Axon Guidance—In the developing nervous system, neurons are presented with a
variety of molecular cues that guide axons to their proper targets. HS sulfation has been
implicated in axon targeting through the interaction of the HS proteoglycan glypican-1 with
Slit, a secreted protein important for axon guidance, axon branching, and neuronal cell
migration.313,314 Slit repels axonal growth by binding to the Robo receptor.314,315 Removal
of HS by heparinase treatment or addition of exogenous HS containing specific sulfation
patterns inhibits Slit binding to Robo and abolishes the axonal repulsion mediated by
Slit.304,315 These results suggest that HS and particular HS sulfation patterns play important
roles in mediating the chemotropic actions of Slit. In other studies, HS sulfation was shown
to be critical for neuronal outgrowth and axon guidance in Caenorhabditis elegans. Using
genetic approaches, Hobert and colleagues demonstrated that certain neuronal subtypes
require the HS-modifying enzymes C5-epimerase, 2-O-sulfotransferase, and 6-O-
sulfotransferase for proper axon guidance.316 Interestingly, other subclasses of neurons
require only the C5-epimerase or 2-O-sulfotrans-ferase, and some neuronal subtypes do not
require any of the HS modifying enzymes. Cumulatively, these studies demonstrate that HS
sulfation patterns play important roles in neuronal development and may encode axon
guidance cues to direct neurons to their proper targets in vivo.
5.2.3. Spinal Cord Regeneration—Chondroitin sulfate proteoglycans (CSPGs) are
crucial components of perineuronal nets, structures of ECM molecules surrounding the soma
and proximal dendrites of certain neurons in the brain and spinal cord.317,318 CSPGs and
other ECM molecules are recruited to sites of CNS injury and form a portion of the glia scar,
a structure that inhibits axonal regeneration and contributes to permanent paralysis in vivo.
Several groups have demonstrated the importance of CSPGs and their associated sugar
chains in mediating neuronal inhibition after spinal cord injury. For instance, CSPGs have
been shown to inhibit the neurite outgrowth of DRG and CGN neurons in vitro.319,320
Moreover, degrading CS chains with chondroitinase ABC (ChABC), an enzyme that cleaves
CS into disaccharide units, reverses the inhibitory effects of CSPGs on neurite
outgrowth.321,322 Most notably, Fawcett, McMahon, and colleagues discovered that ChABC
digestion of CSPGs promotes spinal cord regeneration in vivo, with concomitant partial
recovery of proprioceptive behaviors and locomotor skills in mice.323,324 These and other
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studies indicate that CSPGs exert a crucial inhibitory role on neuronal regeneration and
represent valid targets for therapeutic intervention. Such studies also underscore the
importance of CS glycosaminoglycans in this process and the need to further understand the
molecular mechanisms and sulfation patterns involved in directing their activity.
5.3. Challenges to the Study of GAGs
While GAGs play a fundamental role in many neurobiological processes, a molecular level
understanding of the roles of specific sulfation sequences in mediating GAG functions is
largely unknown. GAG biosynthesis is not template driven and lacks the proofreading
capabilities of DNA biosynthesis, which results in greater chemical heterogeneity and
structural diversity within GAG chains. Thus, GAGs purified from natural sources are often
mixtures of compounds that contain different sulfation patterns and chain lengths.
Characterization of these structures is challenging and is often described simply in terms of
the percent composition of distinct sulfated disaccharide subunits. Little is known about the
precise linear sequences of GAG polysaccharides, although methods to sequence short
oligosaccharide sequences are becoming available.325–327 Given these challenges, the
synthesis of homogeneous oligosaccharides containing defined sulfation sequences has the
potential to significantly advance our understanding of the structure–activity relationships of
glycosaminoglycans. Here, we will highlight chemical approaches that have helped to
decipher the roles of GAGs in the nervous system and efforts to develop GAG-based
therapeutics for neurodegenerative diseases.
5.4. Synthetic Molecules for Probing Structure–Activity Relationships
As described above, the sulfation patterns of GAGs are important for directing their
neurobiological functions. Although genetic approaches have revealed crucial roles for
GAGs in neural development, such experiments lead to global changes in sulfation
throughout the carbohydrate chain, precluding the identification of specific sulfation motifs
responsible for biological activity. The use of chemically defined small-molecule GAGs has
provided insight into their neurobiological roles and demonstrated the importance of specific
sulfation sequences in mediating GAG functions.
5.4.1. Synthesis of Glycosaminoglycans—Early work on glycosaminoglycans
focused primarily on the synthesis of heparin oligosaccharides.328–336 Heparin has been
used since the 1940s as an antithrombic agent, and a unique heparin pentasaccharide
sequence was discovered in the 1980s as a potent factor Xa inhibitor.298 The first syntheses
of heparin pentasaccharides required over 60 steps, produced heparin in relatively low yield,
and were impractical for the development of synthetic drugs. Since then, the efforts of
multiple laboratories have contributed methods that allow for efficient syntheses of heparin,
HS, and their analogues.337–344
GAGs are notoriously difficult to synthesize, requiring the formation of stereospecific
glycosidic linkages, uronic acid donors and acceptors with low chemical reactivity, and
sophisticated protecting group strategies to effect regioselective sulfation. Heparin, HS, and
DS oligosaccharides also necessitate efficient syntheses of the challenging L-idopyranosyl
sugar. The synthesis of GAGs has been summarized in several excellent reviews (see refs
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337, 344–347) Recently, there has been great interest in generating libraries of sulfated
compounds to probe the role of sulfation and identify biologically active sulfation
motifs.2,285,339,340,342,348 In general, these approaches implement modular, convergent
synthetic strategies that afford multiple sulfated structures from a common disaccharide
synthon and thus minimize the number of steps.
Other strategies have employed chemoenzymatic routes to generate defined GAG
oligosaccharides. Kobayashi and co-workers have capitalized on the promiscuity of
hyaluronidase, an enzyme that normally catalyzes the hydrolysis of chondroitin in vivo, to
effect glycosidic bond formation and generate GAG polymers.349–353 They were able to
demonstrate the efficient polymerization of N-acetylhyalobiuronate [GlcAβ (1–3)GlcNAc]
and N-acetylchondrosine [GlcAβ (1–3)GalNAc] derivatives to form HA and nonsulfated
chondroitin, respectively, as well as unnatural chondroitin analogues.349 DeAngelis and
colleagues have generated chimeric unsulfated GAG oligo- and polysaccharides through the
use of hyaluronan and chondroitin synthases.354 Notably, Rosenberg and co-workers have
developed a chemoenzymatic route toward the synthesis of a specific sulfated HS
pentasaccharide that binds to antithrombin III.355 The authors used a nonsulfated
polysaccharide obtained from E. coli as starting material and synthesized the final product
using six recombinant sulfotransferases. This route achieved the synthesis of the sulfated
structure in just six steps with at least a 2-fold greater yield relative to total chemical
synthesis,356 although it was performed only on a milligram-scale. Thus, chemoenzymatic
synthetic strategies can complement traditional synthetic approaches to provide facile,
efficient methods to generate structurally defined natural and unnatural GAGs.
5.4.2. Effects of HS and DS Molecules on Neuronal Growth—Early studies of
GAG function in the nervous system involved the use of GAGs purified from various
biological sources, such as shark cartilage, bovine kidney, and the surface of tumor
cells.357–360 For example, Prochiantz and Rousselet demonstrated that natural HS
polysaccharides enhance axonal outgrowth, while inhibiting dendrite elongation. In contrast,
DS polysaccharides favor the growth of both axons and dendrites.358 Small-molecule di-
through hexasaccharides derived from HS and DS polysaccharides were found to have
similar effects as the natural polysaccharides, providing the first evidence that the biological
activity of GAGs can be recapitulated in short oligosaccharides.357,358
5.4.3. Neuroactive Small-Molecule Chondroitin Sulfates—Paradoxically, CS has
been shown to both stimulate and inhibit neuronal growth, depending on the cellular
context.361–363 However, the molecules used in those studies were ~200 saccharides in
length, poorly defined, and heterogeneously sulfated. To address whether specific sulfation
patterns were important for neuronal growth, Hsieh-Wilson and colleagues used a modular
strategy to synthesize pure, chemically defined CS-E, CS-C, CS-A, and CS-R
tetrasaccharides (Figure 16).283 Tetrasaccharides bearing the CS-E motif were found to
stimulate the outgrowth of various neuron types, including hippocampal and dopaminergic
neurons.283,285 A tetrasaccharide was found to be the minimal motif required for activity, as
CS-E disaccharides had no effect on neurite outgrowth.285 Furthermore, tetrasaccharides
bearing other prominent CS sulfation patterns found in the brain, such as CS-C and CS-A,
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had no significant growth-promoting activity, underscoring the importance of specific
sulfation patterns in directing CS activity. Notably, the unnatural CS-R motif could not
stimulate neurite outgrowth, despite having the same overall negative charge as CS-E.283
Thus, the precise arrangement of sulfate groups along the carbohydrate backbone is critical
for the growth-promoting activity of CS, rather than nonspecific electrostatic interactions.
Together, these results provide direct evidence for the existence of a “sulfation code” that
dictates the neurobiological functions of CS.
5.5. Carbohydrate Microarrays for Studying GAG–Protein Interactions
Microarray technology has revolutionized the discovery of biological information obtained
from both genomics and proteomics experiments. More recently, the advent of carbohydrate
microarrays has made a similar impact on our understanding of protein–carbohydrate
interactions.283,304,364–376 Carbohydrate microarrays provide a powerful tool for the rapid
interrogation of these interactions in a high-throughput, chip-based format. They have also
allowed for systematic investigations into the role of specific sulfation patterns in mediating
the biological activities of GAGs.
5.5.1. Oligosaccharide Microarrays—As described above, studies using chemically
defined oligosaccharides have implicated a tetrasaccharide bearing the CS-E sulfation motif
as important for neurite outgrowth. To gain insight into the molecular mechanisms
underlying its biological activity, the binding of various CS molecules to a panel of neuronal
growth factors was examined using carbohydrate microarrays.283 CS oligosaccharides were
synthesized with an allyl functionality at the reducing end of the sugar. Ozonolysis, followed
by reaction with 1,2-(bisaminooxy)ethane converted the allyl group to an aminooxy
functionality for rapid conjugation of the oligosaccharides to aldehyde-coated slides.283,374
Robotically printed glass slides were analyzed for the binding of CS-A, CS-C, CS-E, and
CS-R tetrasaccharides to growth factors such as midkine, BDNF, and fibroblast growth
factor-1 (FGF-1). Midkine is a growth factor involved in neural tissue development and
repair,377 whereas BDNF is a neurotrophin involved in nervous system development,
synaptic plasticity, and neurodegenerative disease.378 Both midkine and BDNF were found
to preferentially interact with the CS-E tetrasaccharide over other sulfation motifs. In
contrast, FGF-1 did not interact with any CS molecules, consistent with earlier observations
and further corroborating the method.309,379 Importantly, the novel interactions identified
using these microarrays were validated in cellular assays and demonstrated to be important
for CS-E-mediated neuronal growth. Blocking midkine, BDNF, or their cognate receptors
using selective antibodies inhibited the neurite outgrowth induced by CS-E tetrasaccharides.
These studies illustrate the power of carbohydrate microarrays to elucidate molecular
interactions and mechanisms involving specific GAG sequences.
Seeberger and co-workers have used oligosaccharide microarrays to study the binding of
heparin di-, tetra-, and hexasaccharides to FGF-1 and FGF-2.371,380 Both heparin tetra- and
hexasaccharides were shown to interact with these growth factors, consistent with the
minimum structural requirements known to bind FGF-1 and FGF-2. In the future, it will be
interesting to examine the interactions of a panel of neuronal growth factors with different
sulfated HS analogues and to compare their binding to both sulfated HS and CS molecules.
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5.5.2. Polysaccharide Microarrays—In addition to oligosaccharide microarrays,
polysaccharide microarrays have been developed and exploited for the study of GAG
function. Although the structures of polysaccharides are less well-defined, polysaccharide
microarrays can be readily assembled from commercially available compounds and can
provide valuable information. For instance, such microarrays have revealed key structural
determinants responsible for protein binding, such as the importance of sulfation at specific
positions.283,304,374 They have also enabled rapid comparisons across different protein
families or functional classes, as well as between different GAG subclasses (e.g., HA, HS,
CS, DS, KS), providing a more comprehensive investigation into protein-binding specific-
ity.304 Using polysaccharide microarrays, Shipp and Hsieh-Wilson found HS to interact in a
sulfation-dependent manner with axon guidance proteins, such as Slit2, netrin1, ephrinA1,
ephrinA5, and semaphorin5B.304 Slit2 interacted preferentially with 6-O-sulfated and N-
sulfated HS sequences. Furthermore, the sulfation preferences of Slit2 and netrin1 were
validated in cellular assays using differentially sulfated HS polysaccharides, which were
shown to inhibit Slit- and netrin-mediated axonal guidance and neuronal migration.
Cumulatively, these studies demonstrate the ability of carbohydrate microarray technologies
to distinguish the influence of fine structural details such as sulfation pattern on GAG–
protein interactions. This methodology also provides a powerful platform to rapidly screen
thousands of carbohydrate–protein interactions, which can help to identify the proteins
mediating the biological functions of GAGs and uncover the diverse biological functions
governed by these extraordinary molecules.
5.6. Glycosaminoglycan-Based Therapeutics
Historically, heparin oligo- and polysaccharides are known for their therapeutic value for the
treatment of blood coagulation and deep vein thrombosis (DVT). Studies on a synthetic
sulfated pentasaccharide of heparin have helped to uncover the mechanism of heparin’s
anticoagulant activity and led to development of the drug Arixtra for the treatment of
pulmonary embolism and DVT.337 The development of additional GAG therapeutic
molecules is underway to create potential treatments for cancer metastasis, Alzheimer’s
disease, and axonal regeneration. Here, we review the current literature on GAGs as
potential therapeutic agents for neurodegenerative disorders.
5.6.1. Prion Diseases—Transmissible spongiform encephalopathies are prion diseases
characterized by vacuolation, amyloid plaques containing amyloid fibrils, and neuronal
degeneration. These diseases include scrapie, bovine spongiform encephalitis (also known
as “mad cow disease”), Kuru (human form of transmissible spongiform encephalitis),
Creutzfeldt–Jakob disease (CJD), and Gerstmann–Straussler–Scheinker disease.381 The
prion protein is the main component of amyloid fibrils, which are similar to the β-amyloid
fibrils characteristic of Alzheimer’s disease.382 These proteins generally induce
conformational changes of the protein from α-helix to β-sheet, which leads to aggregation
and formation of plaques.383,384 Thus, molecules that inhibit prion protein aggregation and
plaque formation have potential therapeutic value.
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Avila and co-workers have investigated the effects of sulfated polysaccharides (heparin, KS,
and CS), as well as the unsulfated polysaccharide HA, on prion polymerization in vitro.385
Sulfated GAGs led to significant inhibition of prion polymerization through the direct
interaction of these molecules with prion amyloid fibrils. No polymerization inhibition or
neuroprotection was observed with HA, suggesting that sulfation is critical for the observed
activity.385 Interestingly, differentially sulfated GAGs led to different morphologies of the
resulting fibrils. However, the polysaccharides used were from natural sources and thus
contained some degree of heterogeneity. Systematic studies with GAGs of defined length
and sulfation pattern have not yet been performed and may reveal new molecules with
optimal activity as potential treatments for prion diseases.
5.6.2. Alzheimer’s Disease—Glycosaminoglycans have also been investigated as
potential treatments for the pathogenesis and senile dementia associated with Alzheimer’s
disease. HS proteoglycans are believed to promote aggregation of the β-amyloid peptide and
hence contribute to the disease pathogenesis.386–391 In addition, HS has been shown to
protect β-amyloid aggregates from proteolytic degradation392 and microglia phagocytosis in
rodent brains,393,394 resulting in the persistence of amyloid deposits.395 Heparin also
enhances the synthesis, secretion, and cleavage of the β-amyloid precursor protein (APP) in
vitro, suggesting that heparin may contribute to amyloid fibril formation.396 Together, these
studies suggest roles for GAGs in the etiology of Alzheimer’s disease and new potential
avenues for therapeutic treatment.
Low molecular weight (LMW) heparin fragments and heparin disaccharides have been
examined for their ability to affect amyloidogenesis in Alzheimer’s disease. These heparin
fragments, especially heparin disaccharides, inhibit binding of heparin to the β-amyloid
peptide, as well as heparin-stimulated APP secretion in vitro. All LMW fragments used in
these studies were found to cross the blood–brain barrier in an in vitro cell culture model,
whereas passage of polysaccharides was significantly inhibited.397 Injection of LMW
heparins into rat brains has also been shown to attenuate protein toxicity due to tau,398,399 a
microtubule-associated protein whose aggregation is associated with the pathogenesis of
Alzheimer’s disease.400 In addition, LMW heparins attenuate β-amyloid-mediated
neurotoxicity and inflammation.401 Thus, LMW heparin molecules and their derivatives
might be useful therapeutic agents to prevent or slow the progress of amyloidogenesis
associated with Alzheimer’s disease.397,402
Two sulfated LMW glycosaminoglycans and their derivatives are currently in clinical trials
for the treatment of Alzheimer’s disease and senile dementia, and one drug, Ateroid
marketed by Cornelli Consulting, is currently sold in Europe and Asia. Ateroid is mostly
composed of LMW heparin and is used for the treatment of old-age dementia, ischemic
vascular dementia, and multi-infarct dementia. Alzhemed (tramiprosate; 3-amino-1-
propanesulfonic acid) is a small synthetic GAG-based mimetic currently in phase III clinical
trials that inhibits the formation of β-amyloid fibrils.403 Results have been promising from
phase II clinical trials in patients with mild-to-moderate Alzheimer’s disease, suggesting the
potential of such approaches for the treatment of this disorder.
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5.6.3. Future Challenges—Elucidating the molecular mechanisms governing the modes
of glycosaminoglycan action, such as the presence of a “sulfation code”, will greatly
facilitate the development of new therapeutics specifically targeted to treat disorders such as
Alzheimer’s disease. In addition, recently identified glycosaminoglycan mimetics such as
Alzhemed can improve the pharmacokinetic properties of the molecules and create superior
therapeutic agents. Given the scope of the current chemical methodology to study GAGs and
their interactions, GAG-based therapeutic molecules are becoming highly attainable and
may prove effective avenues for the treatment of diseases. As in the case of Arixtra,
understanding the structure–activity relationships of GAGs and the “sulfation code” may
yield molecules with fewer off-target side effects and enhanced therapeutic properties.
6. Summary and Future Directions
The development of new chemical approaches to investigate the biological functions of
carbohydrates has accelerated our understanding of glycan structures and their contributions
to neurobiology, cell signaling, and disease. These studies have revealed crucial roles for
glycans in mediating neuronal growth, adhesion, migration, and regeneration. In addition,
studies have implicated carbohydrates in modulating cell signaling, gene expression, and
synaptic plasticity. As glycans are involved in a myriad of biological functions,
understanding glycan function should continue to provide key insights into the molecular
mechanisms underlying fundamental neurobiological processes. Moreover, our ability to
understand and manipulate such processes using small molecules and glycan mimetics holds
promise for many neurological disorders for which there are currently little or no therapeutic
remedies.
The emergence of chemical technologies for labeling, detection, synthesis, and mimicry are
slowly becoming standard in the field for investigating glycan function, and many of these
tools are now commercially available. The ability to screen high-throughput carbohydrate
microarrays should reveal hundreds of new molecular interactions with growth factors and
other proteins. Such technologies allow the ability to profile oligosaccharide–protein binding
interactions in ways that had only previously been available for protein and DNA
interactions. In addition, these arrays may be useful for diagnostic testing, because many
glycans are dysregulated in various disease states. The ability to chemically tag
oligosaccharides has revolutionized glycoproteomics, and we are just on the cusp of
uncovering a wealth of new information in the coming years in relation to signaling
pathways and disease states. Furthermore, the synthesis of oligosaccharides and glycan
mimetics has revealed detailed information regarding the structure–activity relationships of
glycans and should impact investigations into new drugs or pathways for therapeutic
intervention. Lastly, these versatile chemical tools enable analysis of glycans and
perturbations in glycan function in vivo that until now have been unprecedented. As the
repertoire of chemical tools for investigating glycan functions expands, an increasing
number of oligosaccharide-mediated signaling pathways may be targeted for therapeutic
intervention. The study of glycan structures should also reveal new biomarkers for early
detection of certain diseases, for monitoring disease progression, or for measuring drug
efficacy. We are only at the beginning of what promises to be an exciting new era for the
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field of glycomics, and there are many discoveries and applications still waiting to be
explored.
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Common structures of sialic acid derivatives: neuraminic acid (Neu), N-acetylneuraminic acid (Neu5Ac), N-glycolylneuraminic
acid (Neu5Gc), and deaminoneuraminic acid (KDN).
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Structures of gangliosides that bind to MAG. Neu5Ac = N-acetylneuramic acid; Gal = galactose; GalNAc = N-
acetylgalactosamine; Glc = glucose; Cer = ceramide.
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Synthetic sialic acid analogues tested for binding to MAG. Positions important for MAG interactions are shown in red.
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Structure of (A) a potent disialyl MAG inhibitor and (B) a simplified mimic of the ganglioside GQ1bα with enhanced binding
affinity to MAG relative to Neu5Acα(2–3)Galβ(1–3)-GalNAc.
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(A) Mannosamine derivatives used for metabolic labeling (R = H or Ac) and (B) chemoselective labeling reaction after
treatment of cells with ManLev (R = biotin).
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Structures of various fucose derivatives and 2-dGal.
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Inhibition of Fucα(1–2)Gal linkages with 2-dGal leads to stunted neurite outgrowth in hippocampal neurons cultured for 4 days
in vitro (DIV). D-Gal is able to rescue the effects of 2-dGal. 3-dGal has no effect. White bar indicates 45 μm. Images courtesy of
C. Gama.
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Chemical probe for imaging lectin receptors (top) and staining of hippocampal neurons in culture (bottom panels) with the probe
demonstrating the presence of Fucα(1–2)Gal lectins along the cell body and neurites. Cells were treated with 3 mM of the
imaging probe (A) or biotin (B), labeled with a streptavidin–dye conjugate, and imaged by fluorescence microscopy. Images
courtesy of C. Gama.
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(A) Chemoenzymatic approach for tagging O-GlcNAc glycosylated proteins, (B) UDP–azidogalactose probe for [3 + 2]
cycloaddition chemistry using the chemoenzymatic approach, and (C) GlcNAz and biotin phosphine probe for metabolic
labeling of O-GlcNAc-modified protein using the Staudinger ligation.
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BEMAD approach for mapping O-GlcNAc glycosylation sites.
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A fluorescence resonance energy transfer (FRET)-based sensor to detect O-GlcNAc glycosylation levels.
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QUIC-Tag approach for quantifying dynamic changes in glycosylation.
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Structures of GAG subclasses. Potential sulfation sites are indicated in red. R = SO3− or H; R1 = SO3−, H, or Ac; n = ~10–200.
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CS-E, -A, -C, and -R tetrasaccharides. Only the CS-E tetrasaccharide promotes neurite outgrowth.
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